

# Joseph Meserve

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7768880/publications.pdf>

Version: 2024-02-01

15  
papers

522  
citations

932766

10  
h-index

1058022

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
2	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
3	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
4	Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 374-382.	1.9	54
5	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
6	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
7	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
8	Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. <i>Gastroenterology</i> , 2021, 161, 107-115.e3.	0.6	17
9	Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2728-2740.e1.	2.4	15
10	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
11	Predicting Response to Vedolizumab in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 76.	1.2	11
12	Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2564-2569.	1.1	10
13	In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101619.	1.0	4
14	Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1469-1472.	0.6	4
15	Editorial: risk of pneumonia in IBD "reading between the lines!.. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1490-1491.	1.9	0